Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

Reading the article you posted recently (link attached below)I came across the below paragraph:

"Remdesivir, known also by its brand name "Veklury," is normally used for adults and children over 12 requiring hospitalization for covid-19, and is normally given in a vein by intravenous (IV) infusion one time each day for up to 10 days."



I am of the belief that the FDA limited the dosage far below what IPIX requested for the trial, the patients were mostly very severe with next to no moderate patients, and now we find out that the dosing days for the trial was limited to 3 days for 25% of patients and 5 days for the remaining patients. All in all, both the dosage and dosings were quite limited due to normal dosing for Rems.... so Brilacidin not performing to the level we expected was a given before the trial even began.

Kind of like going hunting with blanks and being disappointed when none of your shots on target were able to bring down your target.

This is why I feel the CU data is the actual part of the testing that will be able to show somewhat what Brilacidin can really do against Covid.

https://www.yahoo.com/finance/gilead-recalls-vials-remdesivir-covid-122120730.html